Full-Time
Senior Business Development Manager
Tides
Posted on 12/16/2025
WuXi AppTec
1,001-5,000 employees
Global contract research, development, manufacturing organization
No salary listed
Remote in Germany
Remote
Remote role; ideally based in Germany, the Netherlands, or Denmark.
 Business & Strategy (1) |
|---|
- BA/BS in Chemistry or Biochemistry and certain professional training or experience in business (i.e. Marketing, Sales experience) is required
- 5+ years’ relevant experience working in oligo or peptide drug development or CRO/CDMO industry
- Hunting and Prospecting for oligo and peptide companies, in need of CMC Development and Manufacturing solutions, who would benefit from WuXi TIDES CDMO services.
- Obtains conferences and meetings to represent WuXi TIDES services to prospective and existing clients via email, phone, and web-conferencing systems.
- Travel to local client meetings when possible.
- Participates in tradeshows to raise profile of WuXi TIDES and generate leads
- Acts upon, refers and follows-up on leads from both sales and marketing campaigns.
- Increase awareness of WuXi TIDES marketing initiatives including scheduling meetings at tradeshows and promoting registrations for webinars and seminars.
- Maintains knowledge of industry trends, funding, regulatory influence, mergers and acquisitions, in-out licensing of products/technologies, government/private grants and contacts, new drug development and approvals, related patent grants and notifications, market growth of small, med, and large cap companies.
- Develops a social network of industry related contacts via LinkedIn and other social networking platforms.
- Proposes new ideas to increase performance for WuXi TIDES goals.
- Documents information in Client Relationship Management (CRM) including contacts, pre-screened/qualified leads, and new account information as required.
- Self-starter
- self-motivated
- highly flexible, with excellent communication skills (verbal, written, and presentation skills) - though these appear under knowledge/skills/abilities; but tool may misclassify.
- Must be organized and detail-oriented.
- Proven track record of simultaneously managing several projects and timelines.
- Ability to perform within a professional environment and use judgment as dictated by the complexity of the situation.
What WuXi AppTec does: It provides a global, integrated open-access platform for contract research, development, and manufacturing services (CRDMO) to the pharmaceutical, biotechnology, and medical device industries. How its products work: Clients access a broad portfolio of capabilities—laboratory testing, process development, and manufacturing—across the full product lifecycle, from discovery and preclinical work to clinical and commercial production, often supported by strategic acquisitions to extend reach. How it differs from competitors: It combines extensive geographic reach with a wide, end-to-end service portfolio in one platform, rather than focusing on a narrow stage or region. What its goal is: To help innovators bring new medicines and healthcare products to market faster and with high quality.
Company Size
1,001-5,000
Company Stage
IPO
Headquarters
Huangpu, China
Founded
2000
Simplify's Take
What believers are saying
- Q1 2026 revenue surged 28.8% to RMB 12.44 billion with 72% adjusted profit growth.
- $510 million Delaware facility occupies 1.74 million sq ft by August 2026.
- Ninth Frost & Sullivan CRDMO Company of the Year Award in 2025 affirms leadership.
What critics are saying
- BIOSECURE Act bans US federal contracts from 2026, cutting 62% US revenue.
- PLA-linked genetic testing triggers US blacklisting and client exodus like Pfizer.
- Lonza undercuts pricing, eroding WuXi Chemistry's 43.7% Q1 2026 growth.
What makes WuXi AppTec unique
- WuXi AppTec's end-to-end CRDMO platform spans discovery to commercialization across small molecules and biologics.
- Global network of 20 sites serves 6,000 customers in 30+ countries from Asia, US, and Europe.
- Open-access model founded in 2000 lowers R&D barriers for pharma and biotech innovators.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Remote Work Options
Growth & Insights and Company News
6 month growth
↑ 0%1 year growth
↓ -1%2 year growth
↑ 0%WuXi AppTec, a global pharmaceutical contract research, development and manufacturing organisation, reported record 2025 results, beating full-year guidance. Total revenue reached RMB 45.46 billion, up 15.8% year-on-year, whilst revenue from continuing operations rose 21.4% to RMB 43.42 billion. Adjusted non-IFRS net profit increased 41.3% to RMB 14.96 billion, with the profit margin rising 5.9 percentage points to 32.9%. The company's backlog for continuing operations grew 28.8% to RMB 58.00 billion. The firm added 839 new molecules to its small molecule development and manufacturing pipeline in 2025, bringing the total to 3,452. WuXi AppTec achieved its first MSCI AAA and CDP Climate Change A ratings during the year.
A Chinese investment firm funded by Yale and Princeton universities has purchased a stake in WuXi AppTec, a Shanghai biotech company that US lawmakers say operates genetic testing centres in coordination with China's People's Liberation Army. The company has faced accusations of assisting Beijing in identifying Uyghur Muslims in Xinjiang. Last year, American legislators warned about WuXi AppTec's military connections and operations. The investment highlights concerns about elite US institutions indirectly funding Chinese companies with military ties through their endowment investments. Neither the investment firm nor the universities have publicly commented on the transaction or its implications for national security.
D3 Bio, a clinical-stage biotechnology company focused on oncology therapeutics, has raised $108 million in a Series B financing round. The round was backed by IDG Capital and SongQing Capital, with participation from existing investors including WuXi AppTec's Corporate Venture Fund, Temasek, HSG, MPCi and Medicxi. The funding will primarily support D3 Bio's planned global Phase III pivotal programme for elisrasib (D3S-001), its lead asset targeting KRAS G12C-mutant cancers. The trials will evaluate elisrasib as monotherapy and in combination treatments across the United States, China and the European Union to facilitate global regulatory submissions. The proceeds will also advance D3 Bio's pipeline of targeted and immuno-oncology programmes with first-in-class or best-in-class potential.
SHANGHAI, March 31, 2025 /PRNewswire/ -- WuXi AppTec, a global company that provides a broad portfolio of RD and manufacturing services to enable companies in the pharmaceutical and life sciences industry, today announced that its Active Pharmaceutical Ingredient (API) manufacturing sites at Changzhou and Taixing in Jiangsu province of China, successfully passed U.S. Food and Drug Administration (FDA) inspections back-to-back in March — both without a single observation and with no Form 483 issued. These achievements further demonstrate WuXi AppTec's unwavering commitment to upholding the highest quality standards and to supporting global healthcare innovators in reliably delivering needed therapies to patients worldwide
WuXi AppTec to spend $510 Million to occupy 1.74 Million square feet of space in Middletown Delaware. WuXi AppTec to spend $510 Million to occupy 1.74 Million square feet of space in Middletown Delaware.Middletown, Delaware — According to state and local development sources, WuXi AppTec plans to invest $510,000,000.00 to build out 1,740,000 square feet of new space in Middletown. The company plans to occupy the new space in Middletown, on or about August 1, 2026. According to the company website As a global company with operations across Asia, Europe, and North America, WuXi AppTec provides a broad portfolio of RD and manufacturing services that enable the global pharmaceutical and life sciences industry to advance discoveries and deliver groundbreaking treatments to patients. Through its unique business models, WuXi AppTecs integrated, end-to-end services include chemistry drug CRDMO (Contract Research, Development and Manufacturing Organization), biology discovery, preclinical testing and clinical research services, advanced therapies CTDMO (Contract Testing, Development and Manufacturing Organization), helping customers improve the productivity of advancing healthcare products through cost-effective and efficient solutions. WuXi AppTec received an AA ESG rating from MSCI for the third consecutive year in 2023 and its open-access platform is enabling more than 6,000 customers from over 30 countries to improve the health of those in need and to realize the vision that every drug can be made and every disease can be treated.To learn more about WuXi AppTec, visit http://www.wuxiapptec.com/Company Contact:Rick Connell, [email protected]://www.linkedin.com/in/rick-connell/857-413-2800SOURCE: http://www.intelligence360.ioCopyright (c) 2025 SI360 Inc